Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 7Unknown 2Withdrawn 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 6Carcinoma, Hepatocellular 5Head and Neck Neoplasms 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms, Squamous Cell 2Glioblastoma 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Incontinence 1Tuberous Sclerosis 1Sarcoma 1Recurrent respiratory papillomatosis 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Postoperative Complications 1Papillomavirus Infections 1Papilloma 1Ovarian Neoplasms 1Orgasm 1Oligodendroglioma 1Neoplasms 1Neoplasm Metastasis 1Myasthenia Gravis 1Melanoma 1Medication Adherence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Withdrawn × Myasthenia Gravis × Clear all
NCT03165435 2018-05-30

A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis

CuraVac

Phase 2/3 Withdrawn

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡